Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ANVS 
Annovis Bio Inc (ANVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ANVS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -93.24% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 29.03M USD | Price to earnings Ratio - | 1Y Target Price 31.2 |
Price to earnings Ratio - | 1Y Target Price 31.2 | ||
Volume (30-day avg) 371620 | Beta 1.65 | 52 Weeks Range 1.43 - 20.00 | Updated Date 04/1/2025 |
52 Weeks Range 1.43 - 20.00 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.31 |
Earnings Date
Report Date 2025-03-27 | When After Market | Estimate -0.2 | Actual -0.43 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -138.27% | Return on Equity (TTM) -3159.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 18482568 | Price to Sales(TTM) - |
Enterprise Value 18482568 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.57 | Shares Outstanding 19486200 | Shares Floating 15671217 |
Shares Outstanding 19486200 | Shares Floating 15671217 | ||
Percent Insiders 14.45 | Percent Institutions 13.25 |
Analyst Ratings
Rating 4.33 | Target Price 34.8 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Annovis Bio Inc
Company Overview
History and Background
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegenerative diseases. Founded in 2008, it focuses on developing therapies for Alzheimer's and Parkinson's diseases.
Core Business Areas
- Drug Development: Developing and commercializing therapeutics targeting neurodegenerative diseases such as Alzheimer's and Parkinson's disease.
Leadership and Structure
Dr. Maria L. Maccecchini is the CEO. The company has a board of directors overseeing its operations and strategy.
Top Products and Market Share
Key Offerings
- Posiphen: Posiphen is an oral drug candidate targeting multiple toxic proteins implicated in neurodegenerative diseases. It's in clinical trials, but currently has no market share. Competitors include companies developing other Alzheimer's and Parkinson's treatments, such as Eli Lilly (LLY) and Biogen (BIIB).
Market Dynamics
Industry Overview
The neurodegenerative disease market is large and growing, with significant unmet medical needs, particularly for Alzheimer's and Parkinson's diseases.
Positioning
Annovis Bio aims to address the root causes of neurodegeneration, potentially offering a disease-modifying approach. This differentiates them from companies focused on symptomatic treatments.
Total Addressable Market (TAM)
The Alzheimer's disease market is estimated to exceed $10 billion globally. Annovis Bio's position depends on clinical trial success and regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel drug platform targeting multiple toxic proteins
- Potential disease-modifying approach
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- No approved products
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new neurodegenerative indications
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- LLY
- BIIB
- ABBV
- SNY
- MRK
Competitive Landscape
Annovis Bio faces stiff competition from larger, established pharmaceutical companies with greater resources. However, its novel approach could provide a competitive edge.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Annovis Bio's historical growth is characterized by preclinical and clinical development of its drug candidates.
Future Projections: Future growth depends on clinical trial outcomes and regulatory approvals, making projections speculative.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Posiphen in Alzheimer's and Parkinson's diseases.
Summary
Annovis Bio is a clinical-stage company with a novel approach to treating neurodegenerative diseases. Its strength lies in its unique drug platform, but it faces significant risks due to its reliance on clinical trial success and limited resources. Positive clinical trial results are crucial for its future prospects. The company needs to secure partnerships to bolster its financial stability and expand its development efforts.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
BIIB
Biogen Inc
BIIB
Biogen Inc
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
SNY
Sanofi ADR
SNY
Sanofi ADR
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry news
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data may be outdated and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Annovis Bio Inc
Exchange NYSE | Headquaters Malvern, PA, United States | ||
IPO Launch date 2010-02-12 | Founder, CEO, President, Interim Principal Financial Officer & Executive Director Dr. Maria L. Maccecchini Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.annovisbio.com |
Full time employees 8 | Website https://www.annovisbio.com | ||
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.